• Home
  • News
  • Calendar
  • About DF/HCC
  • Membership
  • Visitor Center

Chin Hur, MD, MPH


  • Yachimski P, Wani S, Givens T, Howard E, Higginbotham T, Price A, Berman K, Hosford L, Katcher PM, Ozanne E, Perzan K, Hur C.Preference of Endoscopic Ablation Over Medical Prevention of Esophageal Adenocarcinoma by Patients With Barrett's Esophagus.Clin Gastroenterol Hepatol. 2014 Mar 26.
  • Kong CY, Kroep S, Curtius K, Hazelton WD, Jeon J, Meza R, Heberle C, Miller M, Choi SE, Lansdorp-Vogelaar I, van Ballegooijen M, Feuer EJ, Inadomi JM, Hur C, Luebeck EG.Exploring the Recent Trend in Esophageal Adenocarcinoma Incidence and Mortality Using Comparative Simulation Modeling.Cancer Epidemiol Biomarkers Prev. 2014 Apr 1.
  • Yasuda K, Choi SE, Nishioka NS, Rattner DW, Puricelli WP, Tramontano AC, Kitano S, Hur C.Incidence and Predictors of Adenocarcinoma Following Endoscopic Ablation of Barrett's Esophagus.Dig Dis Sci. 2014 Jan 7.
  • Choi SE, Perzan K, Tramontano AC, Kong CY, Hur C.Statins and Aspirin for Chemoprevention in Barrett's Esophagus: Results of a Cost-Effectiveness Analysis.Cancer Prev Res (Phila Pa). 2013 Dec 31.
  • Swan JS, Hur C, Lee P, Motazedi T, Donelan K.Responsiveness of the testing morbidities index in colonoscopy.Value Health.;16(6):1046-53.
  • Shaheen NJ, Hur C.Garlic, silver bullets, and surveillance upper endoscopy for Barrett's esophagus.Gastroenterology. 2013 Aug;145(2):273-6.
  • Yeh JM, Hur C, Schrag D, Kuntz KM, Ezzati M, Stout N, Ward Z, Goldie SJ.Contribution of H. pylori and smoking trends to US incidence of intestinal-type noncardia gastric adenocarcinoma: a microsimulation model.PLoS Med. 2013;10(5):e1001451.
  • Hoshida Y, Villanueva A, Sangiovanni A, Sole M, Hur C, Andersson KL, Chung RT, Gould J, Kojima K, Gupta S, Taylor B, Crenshaw A, Gabriel S, Minguez B, Iavarone M, Friedman SL, Colombo M, Llovet JM, Golub TR.Prognostic gene expression signature for patients with hepatitis C-related early-stage cirrhosis.Gastroenterology. 2013 May;144(5):1024-30.
  • Hur C, Miller M, Kong CY, Dowling EC, Nattinger KJ, Dunn M, Feuer EJ.Trends in esophageal adenocarcinoma incidence and mortality.Cancer. 2013 Mar 15;119(6):1149-58.
  • Ladabaum U, Brill JV, Sonnenberg A, Shaheen NJ, Inadomi J, Wilcox CM, Park WG, Hur C, Pasricha PJ.How to Value Technological Innovation: A Proposal for Determining Relative Clinical Value.Gastroenterology. 2012 Nov 12.
  • Knudsen AB, Hur C, Gazelle GS, Schrag D, McFarland EG, Kuntz KM.Rescreening of persons with a negative colonoscopy result: results from a microsimulation model.Ann Intern Med. 2012 Nov 6;157(9):611-20.
  • Falk GW, Buttar NS, Foster NR, Ziegler KL, Demars CJ, Romero Y, Marcon NE, Schnell T, Corley DA, Sharma P, Cruz-Correa MR, Hur C, Fleischer DE, Chak A, Devault KR, Weinberg DS, Della'Zanna G, Richmond E, Smyrk TC, Mandrekar SJ, Limburg PJ, .A combination of esomeprazole and aspirin reduces tissue concentrations of prostaglandin E(2) in patients with Barrett's esophagus.Gastroenterology. 2012 Oct;143(4):917-26.e1.
  • Hur C, Choi SE, Rubenstein JH, Kong CY, Nishioka NS, Provenzale DT, Inadomi JM.The cost effectiveness of radiofrequency ablation for Barrett's esophagus.Gastroenterology. 2012 Sep;143(3):567-75.
  • Choi SE, Hur C.Screening and surveillance for Barrett's esophagus: current issues and future directions.Curr Opin Gastroenterol. 2012 Jul;28(4):377-81. Review.
  • Omer ZB, Ananthakrishnan A, Nattinger KJ, Cole EB, Lin JJ, Kong CY, Hur C.Aspirin Protects Against Barrett's Esophagus in a Multivariate Logistic Regression Analysis.Clin Gastroenterol Hepatol. 2012 Mar 14.
  • Ananthakrishnan AN, Korzenik JR, Hur C.Can mucosal healing be a cost-effective endpoint for biologic therapy in Crohn's disease? A decision analysis.Inflamm Bowel Dis. 2012 Mar 13.
  • Kong CY, Nattinger KJ, Hayeck TJ, Omer ZB, Wang YC, Spechler SJ, McMahon PM, Gazelle GS, Hur C.The Impact of Obesity on the Rise in Esophageal Adenocarcinoma Incidence: Estimates from a Disease Simulation Model.Cancer Epidemiol Biomarkers Prev. 2011 Oct 11.
  • Ananthakrishnan AN, Hur C, Korzenik JR.Certolizumab Pegol Compared to Natalizumab in Patients with Moderate to Severe Crohn's Disease: Results of a Decision Analysis.Dig Dis Sci. 2011 Sep 11.
  • Ananthakrishnan AN, Hur C, Juillerat P, Korzenik JR.Strategies for the Prevention of Postoperative Recurrence in Crohn's Disease: Results of a Decision Analysis.Am J Gastroenterol. 2011 Jul 26.
  • Ho W, Broughton DE, Donelan K, Gazelle GS, Hur C.Analysis of barriers to and patients' preferences for CT colonography for colorectal cancer screening in a nonadherent urban population.AJR Am J Roentgenol. 2010 Aug;195(2):393-7.
  • Yeh JM, Ho W, Hur C.Cost-effectiveness of endoscopic surveillance of gastric ulcers to improve survival.Gastrointest Endosc. 2010 Jul;72(1):33-43.
  • Yeh JM, Hur C, Kuntz KM, Ezzati M, Goldie SJ.Cost-effectiveness of treatment and endoscopic surveillance of precancerous lesions to prevent gastric cancer.Cancer. 2010 Jun 15;116(12):2941-53.
  • Yachimski P, Lee RA, Tramontano A, Nishioka NS, Hur C.Secular Trends in Patients Diagnosed with Barrett's Esophagus.Dig Dis Sci. 2010 Apr;55(4):960-6.
  • Hur C, Hayeck TJ, Yeh JM, Richards EB, Spechler SJ, Gazelle GS, Kong CY.Development, calibration, and validation of a U.S. white male population-based simulation model of esophageal adenocarcinoma.PLoS ONE. 2010;5(3):e9483.
  • Huang ES, Gazelle GS, Hur C.Consensus Guidelines in the Management of Branch Duct Intraductal Papillary Mucinous Neoplasm: A Cost-Effectiveness Analysis.Dig Dis Sci. 2010 Mar;55(3):852-60.
  • Greenblatt WH, Hur C, Knudsen AB, Evans JA, Chung DC, Gazelle GS.Cost-effectiveness of prophylactic surgery for duodenal cancer in familial adenomatous polyposis.Cancer Epidemiol Biomarkers Prev. 2009 Oct;18(10):2677-84.
  • Hur C,Broughton DE,Kong CY,Ozanne EM,Richards EB,Truong T,Gazelle GS.Patient Preferences for the Chemoprevention of Colorectal Cancer.Dig Dis Sci. 2009 Oct;54(10):2207-14.
  • Pandharipande PV,Harisinghani MG,Ozanne EM,Specht MC,Hur C,Lee JM,Gazelle GS.Staging MR lymphangiography of the axilla for early breast cancer: cost-effectiveness analysis.AJR Am J Roentgenol. 2008 Nov;191(5):1308-19.
  • Hur C,Broughton DE,Ozanne E,Yachimski P,Nishioka NS,Gazelle GS.Patient preferences for the chemoprevention of esophageal adenocarcinoma in Barrett's esophagus.Am J Gastroenterol. 2008 Oct;103(10):2432-42.
  • Yachimski P,Nishioka NS,Richards E,Hur C.Treatment of Barrett's esophagus with high-grade dysplasia or cancer: predictors of surgical versus endoscopic therapy.Clin Gastroenterol Hepatol. 2008 Nov;6(11):1206-11.
  • Pandharipande PV, Gervais DA, Mueller PR, Hur C, Gazelle GS.Radiofrequency Ablation versus Nephron-sparing Surgery for Small Unilateral Renal Cell Carcinoma: Cost-effectiveness Analysis.Radiology. 2008 Jul;248(1):169-78.
  • Yeh JM,Kuntz KM,Ezzati M,Hur C,Kong CY,Goldie SJ.Development of an empirically calibrated model of gastric cancer in two high-risk countries.Cancer Epidemiol Biomarkers Prev. 2008 May;17(5):1179-87.
  • Hur C, Yachimski P.How useful is histologic confirmation of intestinal metaplasia in patients with long-segment Barrett's esophagus?.Nat Clin Pract Gastroenterol Hepatol. 2008 Mar;5(3):140-1.
  • Choi MY, Lauwers GY, Hur C, Willett CG, Chung DC.Microsatellite instability is frequently observed in rectal cancer and influenced by neoadjuvant chemoradiation.Int J Radiat Oncol Biol Phys. 2007 Aug 1;68(5):1584.
  • Hur C, Chung DC, Schoen RE, Gazelle GS.The management of small polyps found by virtual colonoscopy: results of a decision analysis.Clin Gastroenterol Hepatol. 2007 Feb;5(2):237-44.
  • Hur C.Esophageal capsule endoscopy for Barrett's esophagus screening: a hard pill to swallow?.Clin Gastroenterol Hepatol. 2007 Mar;5(3):307-9.
  • Schoen RE, Hur C.What is the clinical importance of small polyps with regard to colorectal cancer screening?.Nat Clin Pract Gastroenterol Hepatol. 2006 Sep;3(9):488-9.
  • Hur C, Wittenberg E, Nishioka NS, Gazelle GS.Quality of life in patients with various Barretts esophagus associated health states.Health Qual Life Outcomes. 2006 Aug 2;4(1):45.
  • Siegel CA, Hur C, Korzenik JR, Gazelle GS, Sands BE.Risks and Benefits of Infliximab for the Treatment of Crohn's Disease.Clin Gastroenterol Hepatol. 2006 Aug;4(8):1017-24; quiz 976.
  • Hur C, Chan AT, Tramontano AC, Gazelle GS.Coxibs versus combination NSAID and PPI therapy for chronic pain: an exploration of the risks, benefits, and costs.Ann Pharmacother. 2006 Jun;40(6):1052-63.
  • Hur C, Gazelle GS, Hsu EH, Halpern EF, Podolsky DK.The effect of prior colonic imaging on endoscopic productivity: potential impact of computed tomographic colonography.Clin Gastroenterol Hepatol. 2005 Nov;3(11):1124-7.
  • Jo WS, Bandipalliam P, Shannon KM, Niendorf KB, Chan-Smutko G, Hur C, Syngal S, Chung DC.Correlation of polyp number and family history of colon cancer with germline MYH mutations.Clin Gastroenterol Hepatol. 2005 Oct;3(10):1022-8.
  • Hur C, Wittenberg E, Nishioka NS, Gazelle GS.Patient preferences for the management of high-grade dysplasia in Barrett's esophagus.Dig Dis Sci. 2005 Jan;50(1):116-25.
  • Hur C, Simon LS, Gazelle GS.Analysis of aspirin-associated risks in healthy individuals.Ann Pharmacother. 2005 Jan;39(1):51-7.
  • Hur C, Gazelle GS, Zalis ME, Podolsky DK.An analysis of the potential impact of computed tomographic colonography (virtual colonoscopy) on colonoscopy demand.Gastroenterology. 2004 Nov;127(5):1312-21.
  • Hur C, Simon LS, Gazelle GS.The cost-effectiveness of aspirin versus cyclooxygenase-2-selective inhibitors for colorectal carcinoma chemoprevention in healthy individuals.Cancer. 2004 Jul 1;101(1):189-97.
  • Hur C, Nishioka NS, Gazelle GS.Cost-effectiveness of aspirin chemoprevention for Barrett's esophagus.J Natl Cancer Inst. 2004 Feb 18;96(4):316-25.
  • Hur C, Nishioka NS, Gazelle GS.Cost-effectiveness of photodynamic therapy for treatment of Barrett's esophagus with high grade dysplasia.Dig Dis Sci. 2003 Jul;48(7):1273-83.
  • Brown NA, Kovacs A, Lui CR, Hur C, Zaia JA, Mosley JW.Prevalence of antibody to human herpesvirus 6 among blood donors infected with HIV.Lancet. 1988 Nov 12;2(8620):1146.